Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience

References

• Ishak KG, Zimmerman HJ. Morphologic spectrums of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:759-86
   PubMed Web of Science ®Google Scholar
• Bateman JR, Pugh RP, Cassidy FR, et al. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971;28:907-13
   PubMed Web of Science ®Google Scholar
• Peppercorn PD, Reznek RH, Wilson P, et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil based therapy for advanced colorectal cancer. Br J Cancer 1998;77:2008-11
   PubMed Web of Science ®Google Scholar
• Doria MIJr, Shepard KV, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy: hepatic toxicity with FUDR. Cancer 1986;58:855-61
   PubMed Web of Science ®Google Scholar
• Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987;107:459-65
   Google Scholar
• Shepard KV, Levin B, Karl RC, et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985;3:161-9
   PubMed Web of Science ®Google Scholar
• Robinson SM, Wilson CH, Burt AD, et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012;19:4287-99
   PubMed Web of Science ®Google Scholar
• Burris HA, Fields FM. Topoisomerase inhibitors. Hematol Oncol Clin North Am 1994;8:333-5
   PubMed Web of Science ®Google Scholar
• Creemers GJ, Lund B, Verweijt J. Topoisomersase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994;20:73-9
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065
   PubMed Web of Science ®Google Scholar
• Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845-53
   PubMed Web of Science ®Google Scholar
• Bilchik AJ, Poston G, Curley SA, et al. Neoadjuvant chem therapy or metastatic colon cancer: a cautionary note. J Clin Oncol 2005;23:9073-8
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6
   PubMed Web of Science ®Google Scholar
• Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110:2761-7
   PubMed Web of Science ®Google Scholar
• Klinger M, Eipeldauer S, Hacker S, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009;35:515-20
   PubMed Web of Science ®Google Scholar
• Pessaux P, Panaro F, Casnedi S, et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case–control study. Eur J Surg Oncol 2010;36:575-82
   Google Scholar
• Available from: http://livertox.nih.gov
   Google Scholar
• Gopal DV, Rosen HR. Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med 2000;107(2):100-2. 105-9. 113-14
   PubMed Web of Science ®Google Scholar
• Nyblom H, Björnsson E, Simrén M, et al. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006;26:840-5
   PubMed Web of Science ®Google Scholar
• Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-22
   PubMed Web of Science ®Google Scholar
• Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009;10:278-86
   PubMed Web of Science ®Google Scholar
• Purohit V, Abdelmalek MF, Barve S, et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 2007;86:14-24
   PubMed Web of Science ®Google Scholar
• Sharma SK1, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-19
   PubMed Web of Science ®Google Scholar
• Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study. Pharmacogenomics J 2008;8:29-33
   PubMed Web of Science ®Google Scholar
• Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-95
   PubMed Web of Science ®Google Scholar
• Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-14
   PubMed Web of Science ®Google Scholar
• Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011;29:667-73
   PubMed Web of Science ®Google Scholar
• Van der Bol JM, Mathijssen RH, Verweij J, et al. CYP3A phenotype-based individualized dosing of irinotecan to reduce interindividual variability in pharmacokinetics and toxicity: result from a randomized trial. J Clin Oncol 2008;26, abstract 2506
   Google Scholar
• Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7
   PubMedGoogle Scholar
• Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer 2012;20:135-9
   Google Scholar
• Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf 2011;10:345-9
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res 2003;23:5173-9
   PubMed Web of Science ®Google Scholar